Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, according to the latest edition of Trinity Life Sciences’ annual Drug Index. The report looked at several factors to rank
read moreOn track to meet their long-stated capacity goal for multiple myeloma therapy Carvykti in 2025, Johnson & Johnson and Legend Biotech are already planning the next phase of their cell therapy manufacturing expansion. More: J&J, Legend to invest 0M in
read moreWhile Stéphane Bancel received a lower-than-targeted bonus on the back of declining revenue and a missed sales goal, his total pay was still a record high. More: Moderna CEO Stéphane Bancel scored pay bump in 2024 despite revenue decline and
read moreAfter Novartis’ Pluvicto shook up iSpot.TV’s monthly rankings of the top TV advertising spenders in pharma to kick off the year, it was back to business as usual in February. More: AbbVie regained TV ad spending lead amid February slowdown,
read moreIn his third year as the CEO of Johnson & Johnson, Joaquin Duato received an overall compensation package of $24.3 million. It was a 14% decrease from his $28.4 million figure in 2023, when he was the highest-paid Big Pharma
read more
Phase 2a TREE study assesses safety and efficacy of leriglitazone More: Minoryx doses first patient with leriglitazone in Rett syndrome study Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals